The business trades at an EV/Sales of 2x(mkt cap 2600+ 400debt) while the acquisition they made was for 200 crores for a biz that does sales of 80 odd crores which works out to around 2.5x (assuming no leverage).
So they paid a higher multiple for a biz that they acquired? Maybe cause Tineta Pharma has higher unit economics. The acquisition hardly adds anything to the topline but maybe pitched as a base to build the india formulation business. Need to understand what is the strategy the company wants to buiild.
| Subscribe To Our Free Newsletter |
